Experimental PAH drug trial halted early
NCT ID NCT05135000
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the arteries in the lungs. The goal was to see if LTP001 could improve blood flow and exercise ability. However, the trial was terminated early, meaning it likely did not show enough promise to continue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LTP001 (an experimental oral drug)
What this could lead to
If it had worked, LTP001 could have pointed toward a new treatment option for pulmonary arterial hypertension, a serious lung condition.
What could go wrong
The trial was terminated early, meaning it likely did not show enough benefit or had safety concerns. It was also a small Phase 2 study, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical Univ of South Carolina
Charleston, South Carolina, 29425, United States
-
Novartis Investigative Site
Caba, Buenos Aires, C1025ABI, Argentina
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Amsterdam, 1081 HV, Netherlands
-
Novartis Investigative Site
Krakow, 31 202, Poland
-
Novartis Investigative Site
Lodz, 91-347, Poland
-
Novartis Investigative Site
Wroclaw, 50-556, Poland
-
Novartis Investigative Site
Málaga, Andalusia, 29010, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08036, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Sheffield, South Yorkshire, S10 2JF, United Kingdom
-
Novartis Investigative Site
London, SW3 6PH, United Kingdom
-
Pulmonary Associates PA
Mesa, Arizona, 85206, United States